Clinical neuropharmacology · 2026
Retrograde Ejaculation Associated With Paliperidone Palmitate: A Case Report.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Yavuzlar Civan Hazal
Аннотация
OBJECTIVES: Retrograde ejaculation is a rare but distressing adverse effect of antipsychotic treatment, primarily mediated by alpha-1 adrenergic receptor antagonism. While this complication has been widely reported with risperidone, reports associated with paliperidone palmitate are extremely limited. This report aims to present a case of paliperidone palmitate-induced retrograde ejaculation and to highlight its clinical implications.
METHODS: This report describes a 49-year-old male who developed retrograde ejaculation during treatment with paliperidone palmitate. Clinical evaluation, including urological assessment, was conducted to exclude organic causes. The temporal relationship between medication exposure, dose adjustment, and symptom progression was carefully assessed.
RESULTS: Retrograde ejaculation emerged under paliperidone palmitate monotherapy, persisted despite dose reduction, and resolved only after discontinuation and switch to aripiprazole. No organic etiology was identified. Partial improvement was observed during cross-titration, with complete resolution following discontinuation.
CONCLUSIONS: Paliperidone palmitate can induce retrograde ejaculation despite its lower alpha-1 adrenergic affinity compared with risperidone. This adverse effect may be underrecognized in clinical practice and can contribute to treatment nonadherence. Proactive assessment and appropriate treatment modification are essential to improve clinical outcomes.
METHODS: This report describes a 49-year-old male who developed retrograde ejaculation during treatment with paliperidone palmitate. Clinical evaluation, including urological assessment, was conducted to exclude organic causes. The temporal relationship between medication exposure, dose adjustment, and symptom progression was carefully assessed.
RESULTS: Retrograde ejaculation emerged under paliperidone palmitate monotherapy, persisted despite dose reduction, and resolved only after discontinuation and switch to aripiprazole. No organic etiology was identified. Partial improvement was observed during cross-titration, with complete resolution following discontinuation.
CONCLUSIONS: Paliperidone palmitate can induce retrograde ejaculation despite its lower alpha-1 adrenergic affinity compared with risperidone. This adverse effect may be underrecognized in clinical practice and can contribute to treatment nonadherence. Proactive assessment and appropriate treatment modification are essential to improve clinical outcomes.